Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARQ-154 Foam 0.3% in Pediatric Scalp and Body Psoriasis
NCT07340216Phase 1Completed
- Sponsor
- Arcutis Biotherapeutics
- Start
- Dec 2025
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of roflumilast vehicle cream in psoriasis, sponsored by Arcutis Biotherapeutics. Primary endpoints: Concentration of Roflumilast and Roflumilast N-Oxide from plasma at 2 weeks, Participant incidence of adverse events at 6 weeks and 2 more. Started Dec 2025; status: completed.
02
Drugs
roflumilast vehicle cream
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT07340216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07340216.